Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Catalent

Drug Delivery Solutions segment up 9% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent

4Q Revenues: $532.2 million (+4%)

4Q Earnings: $58.1 million (earnings were $153.5 million 4Q15)

FY Revenues: $1.9 billion (+1%)

FY Earnings: $111.2 million (-47%)

Comments: Revenue from the Softgel Technologies segment was $224.8 million for the quarter, up 1%. Revenue from the Drug Delivery Solutions segment was $238.2 million, an increase of 9%, primarily driven by increased volumes for fee-for-service development work and analytical testing in the U.S., and increased volumes related to biologics and blow-fill-seal offerings. Revenue from the Clinical Supply Services segment was $81.5 million in the quarter, up 1%. Results were impacted by the temporary suspension of operations at the company’s facility in Beinheim, France, which occurred between November 2015 and April 2016.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters